Literature DB >> 19781861

Sexual and injecting risk behaviours among regular ecstasy users.

Matthew Dunn1, Carolyn Day, Raimondo Bruno, Louisa Degenhardt, Gabrielle Campbell.   

Abstract

Substance users may be at a heightened risk for the transmission of HIV and other blood-borne viral infections (BBVI) through injecting drug use or risky sexual behaviours. The current study aimed to investigate the engagement in BBVI-risk behaviours among a sentinel group of regular ecstasy users in Australia, with a particular focus on sexual practices and describe the occurrence of BBVI testing among this group. Participants were regular ecstasy users recruited across Australia in 2007 who were administered a structured interview that contained questions regarding substance use, sexual behaviours and occurrence of BBVI testing. Results indicate high levels of unprotected sex in the past 6 months (77% reported inconsistent condom use with a regular partner; 54% with a casual partner). Half the sample reported never having an HIV test. Unprotected sex was associated with being heterosexual; despite this, heterosexuals were also less likely to report HIV testing status. These data suggest that targeted health promotion messages may be needed for this group of predominantly young, heterosexual substance users who may fall out of the reach of traditional messages.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19781861     DOI: 10.1016/j.addbeh.2009.09.001

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  2 in total

1.  The effects of psychostimulant drugs on blood brain barrier function and neuroinflammation.

Authors:  Sharanya M Kousik; T Celeste Napier; Paul M Carvey
Journal:  Front Pharmacol       Date:  2012-06-29       Impact factor: 5.810

2.  Correlates of unprotected sex in a sample of young club drug users.

Authors:  Lysa Remy; Joana Narvaez; Anne Sordi; Luciano S P Guimarães; Lisia Von Diemen; Hilary Surratt; Steven Kurtz; Flavio Pechansky
Journal:  Clinics (Sao Paulo)       Date:  2013-11       Impact factor: 2.365

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.